Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million on July 20 in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and...

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and Enso Ventures. Founder...

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress,...

Science 37 Inc. , Culver City, Calif. Business: Supply/Service Date completed: 2016-10-18 Type: Venture financing Raised: $31 million Investors: Redmile Group; Lux Capital; dRx Capital; Sanofi-Genzyme BioVentures...

Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is...

ImmuneXcite Inc. , Watertown, Mass. Business: Cancer, Infectious, Antibodies Date completed: 2016-03-30 Type: Venture financing Raised: $8.6 million Investors: Cormorant Asset Management; Sanofi-Genzyme BioVentures; Partners Innovation Fund Note: The financing is a series A-1 round. WIR...

Traditional VCs are missing from the new series A syndicate backing Yumanity Therapeutics LLC , and the biotech says that was its plan. The neurodegeneration company wanted investors with exceedingly long time horizons and the ability...